An Open-label, Non-controlled, Multicenter, Pilot Trial, Using Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial (NTM) Infection
Phase of Trial: Phase II
Latest Information Update: 20 Sep 2019
Price : $35 *
At a glance
- Drugs Molgramostim (Primary)
- Indications Mycobacterial infections; Mycobacterium avium complex infections; Nontuberculous mycobacterium infections
- Focus Therapeutic Use
- Acronyms ENCORE
- Sponsors Savara Pharmaceuticals
- 01 Apr 2019 According to a Savara Pharmaceuticals media release, the company announced the initiation of this study.
- 01 Apr 2019 Status changed from not yet recruiting to recruiting according to a Savara Pharmaceuticals media release.
- 01 Apr 2019 Planned End Date changed from 15 Apr 2021 to 15 Jun 2021.